收费全文 | 907354篇 |
免费 | 73213篇 |
国内免费 | 2458篇 |
耳鼻咽喉 | 13622篇 |
儿科学 | 25199篇 |
妇产科学 | 25750篇 |
基础医学 | 131688篇 |
口腔科学 | 26492篇 |
临床医学 | 78947篇 |
内科学 | 173494篇 |
皮肤病学 | 18626篇 |
神经病学 | 73456篇 |
特种医学 | 38170篇 |
外国民族医学 | 172篇 |
外科学 | 141692篇 |
综合类 | 24841篇 |
现状与发展 | 2篇 |
一般理论 | 273篇 |
预防医学 | 68861篇 |
眼科学 | 21528篇 |
药学 | 69116篇 |
中国医学 | 2214篇 |
肿瘤学 | 48882篇 |
2018年 | 8682篇 |
2016年 | 8189篇 |
2015年 | 10010篇 |
2014年 | 13733篇 |
2013年 | 19723篇 |
2012年 | 27083篇 |
2011年 | 28088篇 |
2010年 | 16397篇 |
2009年 | 15216篇 |
2008年 | 25465篇 |
2007年 | 27253篇 |
2006年 | 26789篇 |
2005年 | 26264篇 |
2004年 | 25343篇 |
2003年 | 24276篇 |
2002年 | 23165篇 |
2001年 | 36479篇 |
2000年 | 37085篇 |
1999年 | 31344篇 |
1998年 | 9458篇 |
1997年 | 8711篇 |
1996年 | 8597篇 |
1995年 | 8096篇 |
1994年 | 7807篇 |
1992年 | 26782篇 |
1991年 | 26251篇 |
1990年 | 25747篇 |
1989年 | 24791篇 |
1988年 | 23327篇 |
1987年 | 22983篇 |
1986年 | 21828篇 |
1985年 | 21162篇 |
1984年 | 16430篇 |
1983年 | 14049篇 |
1982年 | 8885篇 |
1981年 | 8234篇 |
1980年 | 7695篇 |
1979年 | 16781篇 |
1978年 | 12148篇 |
1977年 | 10221篇 |
1976年 | 9345篇 |
1975年 | 10172篇 |
1974年 | 12662篇 |
1973年 | 12159篇 |
1972年 | 11559篇 |
1971年 | 10706篇 |
1970年 | 10242篇 |
1969年 | 9918篇 |
1968年 | 8913篇 |
1967年 | 8237篇 |
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献Methods: A retrospective analysis was performed to identify patients with isolated PCL injuries that underwent reconstruction between 2001 and 2014. Patients with multi-ligamentous injury or another concomitant knee pathology were excluded. Medical records were reviewed for demographic, clinical and operative data. Patients were contacted for administration of a telephone-based questionnaire which included the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation form, Lysholm-Tegner scales, Marx activity scale (MAS), return to sport status, and patient satisfaction instruments.
Results: A total of 15 isolated PCL reconstructions in 14 patients with a mean age of 27.5 years (range 17–43) met the study inclusion criteria; mean follow up was 6.3 years (range 1.4–15.2). Pre-operatively, the primary complaint was knee instability in all patients; on physical examination, lack of a firm end point during posterior drawer testing was found in 93% (14/15) of the knees. In total, 12 of 15 knees underwent transtibial, single-bundle PCLR and three of 15 underwent tibial inlay, double bundle PCLR. Graft types included: quadriceps autograft (7/15), Achilles allograft (6/15), and hamstring autograft (2/15). There were no graft failures in our patient cohort. At most recent follow up the mean scores respectively on the IKDC form, Lysholm-Tegner scales and MAS were (standard deviation): 77.3 (16.5), 83.1 (17.9), 6.13 (2.6), and 7.1 (6.0). All fourteen patients were athletes prior to their injury and 79% (11/14) returned to sport and overall patient satisfaction was 9.2/10.
Conclusions: Isolated PCLR provides good outcomes at mean medium-term follow up with restoration of function, high rate of return to sport and overall patient satisfaction. 相似文献